BigHat Biosciences designs next-generation protein therapeutics with a closed-loop AI platform linking generative design to high-throughput experimentation, now advancing its first clinical program.
Products & media
Behind the scenes: the platform connecting design and data at scale
An automated antibody discovery and engineering platform combining high-throughput wet-lab characterization with machine learning-guided design cycles.
A CDH17-directed antibody-drug conjugate in Phase 1 development for gastric and other advanced gastrointestinal cancers.
An undisclosed-target T-cell engager-plus program in development for oncology.
An AI platform that orchestrates antibody models and datasets and connects computational designs with BigHat's automated laboratory workflows.
A CEACAM6×CD3 T-cell engager program in development for solid tumors.
An undisclosed-target T-cell engager program in development for inflammatory and immunological disease.
Team
Jobs
See all jobs for BigHat Biosciences here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels
